FDA Approvals, New Appointments, and Official Statements - Research Report on Pfizer, Aetna, Lilly, GSK, and Sanofi Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 27, 2013 NEW YORK, November 27, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Aetna Inc. (NYSE: AET), Eli Lilly & Co. (NYSE: LLY), GlaxoSmithKline plc (ADR) (NYSE: GSK), and Sanofi SA (ADR) (NYSE: SNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research Report On November 21, 2013, Pfizer Inc. (Pfizer) announced that the U.S. Food and Drug Administration (FDA) has granted Pfizer's XALKORI (crizotinib) regular approval for the treatment of patients with metastatic ALK-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. According to the Company, the FDA's approval marks the conversion of an accelerated approval to a regular approval and is based on data from pivotal Phase 3 PROFILE 1007 confirmatory trial comparing XALKORI to standard chemotherapy in previously treated patients. Garry Nicholson, President and General Manager, Pfizer Oncology Business Unit, said, "XALKORI has dramatically changed the treatment landscape for patients with advanced ALK-positive NSCLC. Achievement of this milestone underscores Pfizer's commitment to provide physicians with effective cancer therapies for their patients." The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d702_PFE -- Aetna Inc. Research Report On November 20, 2013, Aetna Inc. (Aetna) announced that it has named Yehong Zhang, Ph.D., as General Manager, Greater China, effective immediately. According to Aetna, Dr. Zhang will be responsible for the Company's growth in China, Hong Kong, Macau, and Taiwan. Most recently, Dr. Zhang served as the CEO of Simcere MSD Pharmaceutical Co. Ltd, a joint venture established in 2012 between Simcere and Merck & Co. The Full Research Report on Aetna Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/cbe9_AET -- Eli Lilly & Co. Research Report On November 19, 2013, Eli Lilly & Co. (Lilly) announced a statement from John C. Lechleiter, Ph.D., Chairman and CEO of Lilly, regarding the Company's investment of $7.5 million toward startup of the Indiana Biosciences Research Institute. According to Dr. Lechleiter, "Each year in Indiana, billions of dollars are invested in research and development to advance medical innovation. This institute will help Indiana attract additional global talent and will nurture partnerships across the state and across the country - keeping more research dollars in Indiana and attracting more federal research funds to our state." Dr. Lechleiter added, "In the last decade, Indiana has come of age as a recognized leader in the life sciences - with demonstrated capabilities in biopharmaceuticals, medical devices, and diagnostics, as well as in the areas of animal health and crop sciences. The research institute will fuel Indiana's economy and will underscore the state's position as a life sciences leader. The bio-landscape of Indiana is fertile ground for the Institute, and Lilly is proud to be a part of it." "The IBRI is an R&D model that will help us address some of our most pressing medical needs. Despite important advances in recent years, diseases such as diabetes continue to affect our citizens at alarming rates. By pulling together the best minds for collaborative thinking and research, the new institute will help move us closer to solving some of the world's most difficult challenges in health and nutrition," Dr. Lechleiter concluded. The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/977d_LLY -- GlaxoSmithKline plc (ADR) Research Report On November 20, 2013, GlaxoSmithKline plc (ADR) (GSK) and Amicus Therapeutics (Amicus) announced that Amicus has obtained global rights to develop and commercialize the investigational pharmacological chaperone migalastat HCI as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry. GSK reported that key highlights of the revised agreement include: Amicus will have sole rights to the global drug development, regulatory and commercial activities for the next-generation Fabry ERT (migalastat HCI co-formulated with ERT) as well as migalastat HCI monotherapy; GSK will be eligible for future regulatory and commercial milestone payments, as well as royalty payments; and GSK will invest $3 million in Amicus through an equity investment in a concurrent private placement in public equity (PIPE) transaction. The Full Research Report on GlaxoSmithKline plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/2a35_GSK -- Sanofi SA (ADR) Research Report On November 18, 2013, Sanofi SA (ADR) (Sanofi) announced the Company's decision to stop all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor, fedratinib (SAR302503). The Company reported that after a thorough risk-benefit analysis, including consultation with the U.S. Food and Drug Administration (FDA), study investigators, independent expert neurologists and neuro-radiologists, the Company determined that the risk to patient safety outweighed the benefit that fedratinib bring to patients. Sanofi informed that the decision follows reports of cases consistent with Wernicke's encephalopathy in patients participating in fedratinib clinical trials. The Full Research Report on Sanofi SA (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/29ea_SNY ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
FDA Approvals, New Appointments, and Official Statements - Research Report on Pfizer, Aetna, Lilly, GSK, and Sanofi
Press spacebar to pause and continue. Press esc to stop.